Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity.

Literature DB >> 14702105

The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity.

Abstract

IGF-1 and growth hormone (GH) interact with insulin to modulate its control of carbohydrate metabolism. A new study (see the related article beginning on page 96) shows that blocking the effect of GH in the presence of low serum IGF-1 concentrations enhances insulin sensitivity.

Entities: Chemical Gene

Mesh：

Substances：

Year: 2004 PMID： 14702105 PMCID： PMC300772 DOI： 10.1172/JCI20660

Source DB: PubMed Journal: J Clin Invest ISSN： 0021-9738 Impact factor: 14.808

20 in total

1. Increased overnight growth hormone concentrations in diabetic compared with normal adolescents.

Authors: J A Edge; D B Dunger; D R Matthews; J P Gilbert; C P Smith
Journal: J Clin Endocrinol Metab Date: 1990-11 Impact factor: 5.958

2. Insulin resistance in the liver-specific IGF-1 gene-deleted mouse is abrogated by deletion of the acid-labile subunit of the IGF-binding protein-3 complex: relative roles of growth hormone and IGF-1 in insulin resistance.

Authors: Martin Haluzik; Shoshana Yakar; Oksana Gavrilova; Jennifer Setser; Yves Boisclair; Derek LeRoith
Journal: Diabetes Date: 2003-10 Impact factor: 9.461

Review 3. Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment.

Authors: Z Laron; Y Avitzur; B Klinger
Journal: Metabolism Date: 1995-10 Impact factor: 8.694

4. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes.

Authors: A C Moses; S C Young; L A Morrow; M O'Brien; D R Clemmons
Journal: Diabetes Date: 1996-01 Impact factor: 9.461

5. Acromegaly. Clinical and biochemical features in 500 patients.

Authors: S Ezzat; M J Forster; P Berchtold; D A Redelmeier; V Boerlin; A G Harris
Journal: Medicine (Baltimore) Date: 1994-09 Impact factor: 1.889

6. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance.

Authors: L A Morrow; M B O'Brien; D E Moller; J S Flier; A C Moses
Journal: J Clin Endocrinol Metab Date: 1994-07 Impact factor: 5.958

7. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization.

Authors: R A Rizza; L J Mandarino; J E Gerich
Journal: Diabetes Date: 1982-08 Impact factor: 9.461

8. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults.

Authors: H P Guler; J Zapf; E R Froesch
Journal: N Engl J Med Date: 1987-07-16 Impact factor: 91.245

9. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults.

Authors: J U Weaver; J P Monson; K Noonan; W G John; A Edwards; K A Evans; J Cunningham
Journal: J Clin Endocrinol Metab Date: 1995-01 Impact factor: 5.958

10. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice.

Authors: Shoshana Yakar; Jennifer Setser; Hong Zhao; Bethel Stannard; Martin Haluzik; Vaida Glatt; Mary L Bouxsein; John J Kopchick; Derek LeRoith
Journal: J Clin Invest Date: 2004-01 Impact factor: 14.808

54 in total

Review 1. Early growth conditions, phenotypic development and environmental change.

Authors: Pat Monaghan
Journal: Philos Trans R Soc Lond B Biol Sci Date: 2008-05-12 Impact factor: 6.237

2. The acid-labile subunit is required for full effects of exogenous growth hormone on growth and carbohydrate metabolism.

Authors: Iori Ueki; Sarah L Giesy; Kevin J Harvatine; Jin Wook Kim; Yves R Boisclair
Journal: Endocrinology Date: 2009-03-19 Impact factor: 4.736

3. IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.

Authors: Tirissa J Reid; Zhezhen Jin; Wei Shen; Carlos M Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Jane Kostadinov; Kalmon D Post; Pamela U Freda
Journal: Pituitary Date: 2015-12 Impact factor: 4.107

4. The trajectory of IGF-1 across age and duration of type 1 diabetes.

Authors: Mari Palta; Tamara J LeCaire; Mona Sadek-Badawi; Victor M Herrera; Kirstie K Danielson
Journal: Diabetes Metab Res Rev Date: 2014-11 Impact factor: 4.876

Review 5. Fractones: extracellular matrix niche controlling stem cell fate and growth factor activity in the brain in health and disease.

Authors: Frederic Mercier
Journal: Cell Mol Life Sci Date: 2016-07-30 Impact factor: 9.261

6. Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide.

Authors: Elisabeth Couture; Vanina Bongard; Jean-Christophe Maiza; Antoine Bennet; Philippe Caron
Journal: Pituitary Date: 2012-12 Impact factor: 4.107

Review 7. Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.

Authors: Susan L Samson
Journal: Drugs Date: 2016-09 Impact factor: 9.546

Review 8. New therapeutic agents for acromegaly.

Authors: Shlomo Melmed
Journal: Nat Rev Endocrinol Date: 2015-11-27 Impact factor: 43.330

9. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly.

Authors: Pamela U Freda; Wei Shen; Steven B Heymsfield; Carlos M Reyes-Vidal; Eliza B Geer; Jeffrey N Bruce; Dympna Gallagher
Journal: J Clin Endocrinol Metab Date: 2008-03-18 Impact factor: 5.958

10. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.

Authors: Laura De Marinis; Antonio Bianchi; Alessandra Fusco; Vincenzo Cimino; Marilda Mormando; Laura Tilaro; Gherardo Mazziotti; Alfredo Pontecorvi; Andrea Giustina
Journal: Pituitary Date: 2007 Impact factor: 4.107